Dose of Reality

DOSE OF REALITY: NEW STUDY DEBUNKS BIG PHARMA CLAIMS THAT HIGH PRESCRIPTION DRUG PRICES ARE TIED TO R&D INVESTMENTS

Sep 29, 2022

JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s… Read More

DOSE OF REALITY: BIG PHARMA’S PRICING PRACTICES DRIVE CRISIS OF AFFORDABILITY FOR CANCER PATIENTS

Sep 20, 2022

Shining a Light on How Big Pharma is Rapidly Increasing Prices on Oncology… Read More

DOSE OF REALITY: PATENT HEARINGS OFFER OPPORTUNITY TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTI-COMPETITIVE PRACTICES

Jun 22, 2022

Lawmakers Can Highlight Tactics Designed to Block More Affordable Alternatives… Read More

DOSE OF REALITY: SENATE COMMERCE HEARING OPPORTUNITY FOR LAWMAKERS TO HOLD BIG PHARMA ACCOUNTABLE

May 3, 2022

Lawmakers Should Focus Attention on Brand Name Drug Companies’ Egregious… Read More

DOSE OF REALITY: NEW STUDY FINDS ONE THIRD OF SENIORS DO NOT FILL PRESCRIPTIONS FOR HIGH-PRICE DRUGS USED TO TREAT SERIOUS CONDITIONS

Apr 6, 2022

Academic Study Underscores How Big Pharma’s Price-Gouging on Treatments for… Read More

DOSE OF REALITY: LAWMAKERS MUST HOLD BIG PHARMA ACCOUNTABLE IN SENATE FINANCE HEARING

Mar 14, 2022

Congress Can Refocus Attention on Market-Based Solutions to Crack Down on… Read More

DOSE OF REALITY: NEW ANALYSIS UNDERSCORES HOW OFTEN BIG PHARMA’S PATENTS ARE UNRELATED TO CLINICAL INNOVATION

Jan 19, 2022

Study Finds Just Six Percent of Drug Patents in Infringement Suits Were for… Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART I

Dec 28, 2021

Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch… Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART II

Dec 28, 2021

Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite… Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III

Dec 28, 2021

Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual… Read More